Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_provenance.
• NP939504.RASmJE2a1v1MSjLe_RtaBKsY9nhqN4DtioOLuby2a8HeY130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939504.RASmJE2a1v1MSjLe_RtaBKsY9nhqN4DtioOLuby2a8HeY130_provenance.
• NP799717.RArrg9bvsKCFsuxFqaLgZtajNbftWf4O2G2zQGC0wVCNg130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799717.RArrg9bvsKCFsuxFqaLgZtajNbftWf4O2G2zQGC0wVCNg130_provenance.
• NP450025.RA-_tPdaumdiTPu3JYrSxRVGaPwAVNWlRyBBo0LRd3bAg130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP450025.RA-_tPdaumdiTPu3JYrSxRVGaPwAVNWlRyBBo0LRd3bAg130_provenance.
• assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP530506.RAU4IhgbQW63AOzRs-xX4qFc3fNVYJq_ZDSVdv9oudOa0130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP530506.RAU4IhgbQW63AOzRs-xX4qFc3fNVYJq_ZDSVdv9oudOa0130_provenance.
• NP530515.RARRSOw8CNMGBV-ZR9dj4_BeymfPifH74Kn7JBAI8aM6U130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP530515.RARRSOw8CNMGBV-ZR9dj4_BeymfPifH74Kn7JBAI8aM6U130_provenance.
• NP321170.RAQkx1noVpkhTHGJXMSozHLzB3oUWM6vlpzG3E_XuwYio130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321170.RAQkx1noVpkhTHGJXMSozHLzB3oUWM6vlpzG3E_XuwYio130_provenance.
• assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP583531.RAIYK-SCcJ_7kAPi4BOa0r8opR8qmn-9BdfNDI5UburDQ130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP583531.RAIYK-SCcJ_7kAPi4BOa0r8opR8qmn-9BdfNDI5UburDQ130_provenance.
• NP821101.RAQtp1zzeVnfo3uVYrVB7MUadtEcG2KQM_YSq-dVMAFBw130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP821101.RAQtp1zzeVnfo3uVYrVB7MUadtEcG2KQM_YSq-dVMAFBw130_provenance.
• NP320473.RA2G_FB69je_xwUBwinyIiLlGOBufgh9DgtTjMqRg_pH0130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP320473.RA2G_FB69je_xwUBwinyIiLlGOBufgh9DgtTjMqRg_pH0130_provenance.
• NP321201.RAxXjQjTtBk0cFo-HfZAH6mEO2bKNsztGQqZk9VG8URHo130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321201.RAxXjQjTtBk0cFo-HfZAH6mEO2bKNsztGQqZk9VG8URHo130_provenance.
• NP821102.RALDcxEM2_7__BqbvnWVuVK4s-pJ_caAFx3hp-m-KbKGs130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP821102.RALDcxEM2_7__BqbvnWVuVK4s-pJ_caAFx3hp-m-KbKGs130_provenance.
• NP821104.RAH0Js-LC5UHH7WkqxLE7ubdRzza3TWeYMIWr9UnFh1Ns130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP821104.RAH0Js-LC5UHH7WkqxLE7ubdRzza3TWeYMIWr9UnFh1Ns130_provenance.
• NP821105.RAG1FerGTfpKKYdwwUS0zS7iR_qBQvu6P-f15fFNLWRsU130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP821105.RAG1FerGTfpKKYdwwUS0zS7iR_qBQvu6P-f15fFNLWRsU130_provenance.
• NP821103.RAytPO_wsWZLq3u6ZjKF6TSs9ljeCVVkKrCBtuG9UFwAQ130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP821103.RAytPO_wsWZLq3u6ZjKF6TSs9ljeCVVkKrCBtuG9UFwAQ130_provenance.